Janus Henderson Group
KRTX

Janus Henderson Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Janus Henderson Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,332
Closed -$4.85M – 2594
2023
Q4 		$4.85M Buy
15,332
+1,472
+11% +$286K ﹤0.01% 835
2023
Q3 		$2.34M Buy
13,860
+27
+0.2% +$5.08K ﹤0.01% 1097
2023
Q2 		$3M Buy
13,833
+1,008
+8% +$216K ﹤0.01% 1043
2023
Q1 		$2.33M Buy
12,825
+7,339
+134% +$1.4M ﹤0.01% 1178
2022
Q4 		$1.08M Buy
5,486
+618
+13% +$133K ﹤0.01% 1313
2022
Q3 		$1.09M Buy
4,868
+970
+25% +$196K ﹤0.01% 1596
2022
Q2 		$493K Buy
3,898
+32
+0.8% +$3.68K ﹤0.01% 1778
2022
Q1 		$490K Buy
3,866
+6
+0.2% +$676 ﹤0.01% 1937
2021
Q4 		$506K Buy
3,860
+1,944
+101% +$251K ﹤0.01% 1892
2021
Q3 		$235K Buy
+1,916
New +$221K ﹤0.01% 2001

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Janus Henderson Group's KRTX Position: Q1 2024 in Review

Janus Henderson Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 15,332 shares — an estimated $4.85M sold.

Janus Henderson Group first reported a position in KRTX in Q3 2021 and held it in 10 quarters. The position peaked at $4.85M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Janus Henderson Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Janus Henderson Group sold 15,332 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.85M.
  • Janus Henderson Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
  • Janus Henderson Group's Karuna Therapeutics, Inc. Common Stock position peaked at $4.85M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Janus Henderson Group's 13F filing for Q1 2024, filed 15 May 2024.